Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Empagliflozin for Diabetic Nephropathy in Adolescents With Type 1 Diabetes
NCT07591077Phase 3Completed
- Sponsor
- Ain Shams University
- Start
- Nov 2024
- Primary completion
- Nov 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of empagliflozin in diabetic nephropathy (DN), sponsored by Ain Shams University. Started Nov 2024; status: completed.
02
Drugs
empagliflozin
03
Conditions
diabetic nephropathy (DN)
Beyond the preview
Go deeper on NCT07591077.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07591077.